EN | UA
EN | UA

Help Support

Back

Monthly Casirivimab/Imdevimab infusion lowers COVID risk by 92%, recent study reveals!

Casirivimab/Imdevimab for COVID Casirivimab/Imdevimab for COVID
Casirivimab/Imdevimab for COVID Casirivimab/Imdevimab for COVID

What's new?

Casirivimab plus Imdevimab used monthly can help prevent COVID-19.

A recent phase-1 study published in the International Journal of Infectious Diseases revealed that the monthly subcutaneous (SC) administration of Casirivimab along with Imdevimab (CAS + IMD) was found to be well-tolerated with low immunogenicity and also had a significantly lower risk of COVID-19 occurrence in uninfected adults. Flonza Isa and colleagues assessed the overall effectiveness of CAS + IMD used as frequent monthly SC doses in adult volunteers.

All in all, 969 individuals were randomized (3:1) to receive CAS+IMD 1200 mg or placebo every month for about 6 doses. Primary and secondary endpoints estimated the safety, pharmacokinetics, and immunogenicity. Exploratory efficacy was evaluated by the incidence of COVID-19 or seroconversion from negative to positive for SARS-COV-2 anti-nucleocapsid antibodies indicative of a SARS-CoV-2 infection.

The combination therapy has a relative risk reduction (RRR) of 92.4% and 100% in suspected and confirmed COVID-19, refer to Table 1 below:

Due to lesser anti-drug antibodies developed, the combination group had low immunogenicity. There were no grade ≥3 injection-site reactions. However, more grade 1–2 injection-site reactions were reported in the combination group than placebo. No mortalities were reported.

 

Source:

International Journal of Infectious Diseases

Article:

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Authors:

Flonza Isa et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: